Core Viewpoint - Jiangsu Haobio's stock closed at 86.8 yuan, down 4.67%, with a rolling PE ratio of 158.04 times, significantly higher than the industry average of 49.84 times [1][3] Company Overview - Jiangsu Haobio Biopharmaceutical Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy and autoimmune reagents [2] - The company holds 226 product registration certificates and 57 patents, recognized as a high-tech enterprise and awarded multiple honors, including "Innovative Pioneer Enterprise" and "National Specialized and New 'Little Giant' Enterprise" [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97%, with a gross margin of 57.98% [2] Market Position - As of Q1 2025, 11 institutions held shares in Haobio, with a total of 46.12 million shares valued at 4.007 billion yuan [1]
浩欧博收盘下跌4.67%,滚动市盈率158.04倍,总市值54.73亿元